UTIBRON NEOHALER
LOE ApproachingNDAINHALATIONPOWDER
Approved
Oct 2015
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UTIBRON NEOHALER is an inhaled powder formulation approved in 2015 for chronic obstructive pulmonary disease (COPD) maintenance therapy. The product is a dual bronchodilator combining two active pharmaceutical ingredients delivered via the NEOHALER dry powder inhaler device. Mechanism of action details are not disclosed in available regulatory data.
LOE Approaching2.2 years to LOE
Product faces loss of exclusivity by October 2028; brand team must navigate declining revenues and prepare for generic competition while optimizing remaining patent-protected period.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on UTIBRON NEOHALER at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.